Highly Active Antiretroviral Therapy Of Similar Benefit For HIV-infected Injection Drug Users

Contrary to the belief that HIV-infected injection drug users receive less benefit from highly active antiretroviral therapy, new research finds little difference in the survival rate between IDUs and non-IDUs after 4-5 years of receiving HAART, according to a study in the Aug. 6 issue of JAMA, a theme issue on HIV/AIDS.

Read the whole article on Science Daily

More from Science Daily